{"version":"1.0","provider_name":"INNventa Pharm","provider_url":"https:\/\/innventa-pharm.com\/en\/","author_name":"INNventa Pharm","author_url":"https:\/\/innventa-pharm.com\/en\/author\/innventa-pharm\/","title":"NITROFINN\u00ae - Important additional strenght to Innventa portfolio - INNventa Pharm","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"twvZEoQVS6\"><a href=\"https:\/\/innventa-pharm.com\/en\/news\/nitrofinn-important-additional-strenght-to-innventa-portfolio\/\">NITROFINN\u00ae &#8211; Important additional strenght to Innventa portfolio<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/innventa-pharm.com\/en\/news\/nitrofinn-important-additional-strenght-to-innventa-portfolio\/embed\/#?secret=twvZEoQVS6\" width=\"600\" height=\"338\" title=\"&#8220;NITROFINN\u00ae &#8211; Important additional strenght to Innventa portfolio&#8221; &#8212; INNventa Pharm\" data-secret=\"twvZEoQVS6\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","thumbnail_url":"https:\/\/innventa-pharm.com\/wp-content\/uploads\/2024\/07\/nitrofinn-pic.png","thumbnail_width":1594,"thumbnail_height":1414,"description":"NITROFINN\u00ae &#8211; Important additional strenght to Innventa portfolio After launching of Serapinn forte\u00ae, Forticolinn\u00ae, Miocytinn\u00ae, Laringinn\u00ae and Rhinosinn\u00ae, Innventa is continuing with fulfillment of ambitious 2018 new products launch plan. On 20th of July 2018 in Serbian pharmacies \u00a0is available new product in Innventa urology portfolio &#8211; Nitrofinn\u00ae. Nitrofinn\u00ae is currently the only registered Nitrofurantoin [&hellip;]"}